ALFA Filings
Every announcement, straight from the exchange
Every Akums Drugs & Pharmaceuticals legal & regulatory announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
The First Appellate Authority set aside a Rs.3.59 Crore penalty against Akums' subsidiary, Maxcure Nutravedics. This reversal follows an error in shipping addresses in 2025.
Akums reported a Rs.0.36 Crore penalty on its subsidiary, now set aside by an appellate authority. The company confirmed no financial impact from this regulatory matter.
Akums Drugs' subsidiaries received ₹22.27 Crore in income tax demands regarding historical expenditure disallowances. The company plans to appeal, citing the demands as legally unsustainable.
Akums Drugs received income tax assessment orders totaling ₹133.75 Crore for the 2018-2025 block period. The company plans to appeal these unsustainable demands.